Kim Sablich

Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY.

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai.